Trial ID or NCT#

NCT03945292

Status

recruiting iconRECRUITING

Purpose

The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, ARO-AAT, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).

Official Title

A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul Kwo
Paul Kwo
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology)

Contact us to find out if this trial is right for you.

CONTACT

Swati Toppo
(650) 497-4151